Back to Search Start Over

Prevalence of transmitted drug resistance among HIV-1 treatment-naive patients in Beijing.

Authors :
Song YX
Xin RL
Li ZC
Yu HW
Lun WH
Ye J
Liu A
Li AX
Li JW
Ye JZ
Hao MQ
Lu HY
Sun LJ
Source :
Epidemiology and infection [Epidemiol Infect] 2018 Feb; Vol. 146 (3), pp. 339-344. Date of Electronic Publication: 2018 Jan 18.
Publication Year :
2018

Abstract

To optimise patients' outcomes and gain insight into transmitted drug resistance (TDR) among human immunodeficiency virus (HIV)-1 treatment-naive patients in Beijing, the prevalence of TDR was assessed. Demographic and clinical data of 1241 treatment-naive patients diagnosed between April 2014 and February 2015 were collected. TDR was defined using the Stanford University HIV drug resistance mutations database. The risk factors were evaluated by multi-logistic regression analysis. Among 932 successfully amplified cases, most were male (96.78%) and infected through men having sex with men (91.74%). Genotype were CRF01_AE (56.44%), B (20.60%), CRF07_BC (19.96%), C (1.61%) and other genotypes (1.39%). The overall prevalence of TDR was 6.12%. Most frequent mutations occurred in non-nucleoside reverse transcriptase inhibitors (NNRTIs) (3.11%), followed by protease inhibitors (PIs) (2.25%) and nucleoside reverse transcriptase inhibitors (NRTIs) (1.32%). Furthermore, HIV-1 genotype was associated with high risk of resistance, in which genotype C and other genotype may have higher risk for resistance. The prevalence among treatment-naive patients in Beijing was low. Resistance to NNRTIs was higher than with PIs or NRTIs. Continuous monitoring of regional levels of HIV-1 TDRs would contribute to improve treatment outcomes and prevent failures.

Details

Language :
English
ISSN :
1469-4409
Volume :
146
Issue :
3
Database :
MEDLINE
Journal :
Epidemiology and infection
Publication Type :
Academic Journal
Accession number :
29345606
Full Text :
https://doi.org/10.1017/S0950268817003016